PTEN and prostate cancer: On the other hand, the second generation GEMMs have integrated the single molecular changes observed in human diseases, such as the loss of phosphatase and TENsin homolog (PTEN) and Myc over-expression, but they seem to be unable to reproduce the different stages of prostate cancer [54,61].